Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.

Edward B Garon,Shun Lu,Yasushi Goto,Pedro De Marchi,Luis Paz-Ares,David R Spigel,Michael Thomas,James Chih-Hsin Yang,Andrea Ardizzoni,Fabrice Barlesi,Sergey Orlov,Hiroshige Yoshioka,Giannis Mountzios,Sadhvi Khanna,Claudia Bossen,Mariana Carbini,Sabine Turri,Andrea Myers,Byoung Chul Cho

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 0|浏览36

暂无评分

摘要

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC. No new safety signals were identified with canakinumab.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要